Syntal Capital Partners LLC purchased a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 4,422 shares of the medical research company’s stock, valued at approximately $1,077,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Birch Capital Management LLC grew its position in shares of Amgen by 3.4% during the second quarter. Birch Capital Management LLC now owns 21,721 shares of the medical research company’s stock worth $5,295,000 after acquiring an additional 708 shares during the last quarter. Penserra Capital Management LLC grew its position in shares of Amgen by 69.0% during the first quarter. Penserra Capital Management LLC now owns 42,244 shares of the medical research company’s stock worth $10,510,000 after acquiring an additional 17,253 shares during the last quarter. Optiver Holding B.V. bought a new position in Amgen in the 1st quarter valued at about $5,578,000. Payden & Rygel grew its position in Amgen by 1.5% in the 1st quarter. Payden & Rygel now owns 134,340 shares of the medical research company’s stock valued at $33,425,000 after buying an additional 2,050 shares in the last quarter. Finally, Arlington Financial Advisors LLC grew its position in Amgen by 8.3% in the 2nd quarter. Arlington Financial Advisors LLC now owns 25,724 shares of the medical research company’s stock valued at $6,270,000 after buying an additional 1,962 shares in the last quarter. Institutional investors and hedge funds own 74.73% of the company’s stock.
AMGN has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $255.00 target price for the company in a research report on Tuesday, June 29th. Daiwa Capital Markets lowered shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 target price for the company. in a research report on Thursday. Oppenheimer increased their target price on shares of Amgen from $272.00 to $277.00 and gave the company an “outperform” rating in a research report on Monday, June 7th. SVB Leerink assumed coverage on shares of Amgen in a research report on Sunday, September 19th. They issued a “hold” rating for the company. Finally, William Blair reissued a “hold” rating on shares of Amgen in a report on Friday, September 17th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $245.70.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Monday, August 2nd. The medical research company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.09 by $0.29. Amgen had a net margin of 22.55% and a return on equity of 99.85%. The business had revenue of $6.53 billion during the quarter, compared to analyst estimates of $6.43 billion. Sell-side analysts forecast that Amgen Inc. will post 16.41 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 8th. Investors of record on Tuesday, August 17th were issued a $1.76 dividend. The ex-dividend date was Monday, August 16th. This represents a $7.04 dividend on an annualized basis and a yield of 3.29%. Amgen’s dividend payout ratio is currently 42.41%.
Amgen Company Profile
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
See Also: What are high-yield dividend stocks?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.